Difference between revisions of "Umbralisib (Ukoniq)"
Jump to navigation
Jump to search
m |
|||
| Line 2: | Line 2: | ||
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor | Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor | ||
| − | ==Diseases for which it | + | ==Diseases for which it was used== |
| − | *[[Follicular lymphoma]] | + | *[[Follicular lymphoma - historical|Follicular lymphoma]] |
| − | *[[Marginal zone lymphoma]] | + | *[[Marginal zone lymphoma - historical|Marginal zone lymphoma]] |
== Patient Drug Information== | == Patient Drug Information== | ||
| Line 12: | Line 12: | ||
*2/5/2021: Accelerated approval for adult patients with relapsed or refractory [[marginal zone lymphoma|marginal zone lymphoma (MZL)]] who have received at least one prior [[Regimen_classes#Anti-CD20-based_regimen|anti-CD20-based regimen]]. ''(Based on UNITY-NHL)'' | *2/5/2021: Accelerated approval for adult patients with relapsed or refractory [[marginal zone lymphoma|marginal zone lymphoma (MZL)]] who have received at least one prior [[Regimen_classes#Anti-CD20-based_regimen|anti-CD20-based regimen]]. ''(Based on UNITY-NHL)'' | ||
*2/5/2021: Accelerated approval for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] who have received at least three prior lines of systemic therapy. ''(Based on UNITY-NHL)'' | *2/5/2021: Accelerated approval for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] who have received at least three prior lines of systemic therapy. ''(Based on UNITY-NHL)'' | ||
| + | *6/1/2022: Withdrawn due to safety concerns. ''(Based on UNITY-CLL)'' | ||
==Also known as== | ==Also known as== | ||
| Line 24: | Line 25: | ||
[[Category:CK1 epsilon inhibitors]] | [[Category:CK1 epsilon inhibitors]] | ||
| − | [[Category:Follicular lymphoma medications]] | + | [[Category:Follicular lymphoma medications (historic)]] |
| − | [[Category:Marginal zone lymphoma medications]] | + | [[Category:Marginal zone lymphoma medications (historic)]] |
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
| + | [[Category:FDA withdrawn in 2022]] | ||
[[Category:TG Therapeutics compound]] | [[Category:TG Therapeutics compound]] | ||
Revision as of 01:41, 2 June 2022
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it was used
Patient Drug Information
History of changes in FDA indication
- 2/5/2021: Accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. (Based on UNITY-NHL)
- 2/5/2021: Accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. (Based on UNITY-NHL)
- 6/1/2022: Withdrawn due to safety concerns. (Based on UNITY-CLL)
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq